Immupharma chairman details £2.66m financing and open label extension study – July 2019

7th July 2019 - 3:42 pm

ImmuPharma PLC’s (LON:IMM) chairman Tim McCarthy caught up with Proactive London’s Andrew Scott to discuss the results of a follow-up study which was designed to evaluate Lupuzor’s safety and tolerability.

Share this article